Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Jumped Today

By Joe Tenebruso - May 3, 2021 at 5:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors cheered the vaccine maker's latest move to help end the pandemic.

What happened

Shares of Moderna (MRNA 1.83%) climbed 4% on Monday after the biotech announced a major COVID-19 vaccine supply deal. 

So what

Moderna will provide up to 500 million doses of its coronavirus vaccine to Gavi, the Vaccine Alliance. Gavi works with partners -- such as the World Bank, the Bill & Melinda Gates Foundation, and the World Health Organization (WHO) -- to supply low-income countries with much-needed medicines.

Moderna will deliver 34 million doses to Gavi by the fourth quarter. Gavi also has the option to purchase 466 million more doses next year. Moderna will sell the doses at their lowest tiered price. 

A syringe is in a vial next to other vials.

Moderna's new vaccine supply agreement could help to slow the spread of COVID-19. Image source: Getty Images.

The deal comes after the WHO issued an Emergency Use Listing (EUL) for Moderna's vaccine to prevent COVID-19 in people at least 18 years old on Friday. The EUL is similar in some respects to the Emergency Use Authorization (EUA) granted by the U.S. Food and Drug Administration (FDA) to Moderna in December. The EUL helps other countries accelerate their regulatory approval procedures.

"This is an important milestone as we work to ensure that people around the world have access to our COVID-19 vaccine," Moderna CEO Stephane Bancel said in a press release. 

Now what 

Investors can expect to receive an update on Moderna's overall vaccine sales on Thursday. The company is slated to report its first-quarter financial results before the market open. 

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$174.27 (1.83%) $3.13

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.